Influence of β&lt;sub&gt;3&lt;/sub&gt; Integrin Gene Leu&lt;sup&gt;33&lt;/sup&gt;/Pro&lt;sup&gt;33&lt;/sup&gt; Polymorphism on Primary Glomerulonephritis

Bantis, Christos; Heering, Peter; Aker, Sendogan; Kuhr, Nicola; Grabensee, B; Ivens, Katrin

doi:10.1159/000082867

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical role of PI A2 as a risk factor for cardiovascular disease or diabetic nephropathy is still controversial. (11,(23)(24)(25)(26). Many studies have shown no such association between this polymorphism and an increased risk of myocardial infarction (11,23).…”

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis

Al-Ali,

Al-Muhanna,

Al-Mueilo

et al. 2008

Int. J Biomed Sci.

View full text Add to dashboard Cite

Traditional atherosclerosis risk factors cannot elucidate the increased prevalence of cardiovascular events in end stage renal disease (ESRD) patients on hemodialysis. A previous study has indicated a strong association of the PIA1/A2 polymorphism with myocardial infarction, diabetes and renal allograft rejection. In this investigation, we determined the prevalence of the PIA1/A2 polymorphism of platelet glycoprotein (GP) IIb/IIIa in ESRD patients on hemodialysis in the Eastern Province of Saudi Arabia. The PIA1/A2 polymorphism was determined in 42 ESRD patients receiving hemodialysis and in 49 subjects without current or past history of renal disease. Genotypes were determined by a reverse-hybridization assay and were confirmed by restriction fragment length polymorphism procedures. The PIA2 allele frequency among the control sample was 28.6% (2 were homozygous for PIA2, 23 were homozygous for PIA1, and 24 were heterozygous PIA1/A2). The PIA2 allele frequency among the hemodialysis sample was 50% (2 were homozygous for PIA2, 2 were homozygous for PIA1 and 38 were heterozygous for PIA1/A2). The PIA2 allele frequency among the hemodialysis patients was significantly higher than that in the control group [Odds ratios 2.5 (1.35-4.61), p<0.003; Adjusted odds ratios of 2.21 (1.05-4.65), p<0.036 after adjustment for the presence of diabetes; Simultaneously adjusting the odds ratios for the presence of standard risk factors (diabetes and hypertension) gave an adjusted OR of 6.87 (1.54-30.71), p=0.064]. These results suggest that the PIA2 polymorphism may contribute toward the etiology of cardiovascular diseases in ESRD patients. A further study with a larger sample size is needed to confirm above results.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis

Al-Ali,

Al-Muhanna,

Al-Mueilo

et al. 2008

Int. J Biomed Sci.

View full text Add to dashboard Cite

show abstract

“…In recent years, a very large number of studies has assessed polymorphisms of potential candidate genes in patients with IgAN [Bantis et al 2005, Ohtsubo et al 2005, Schena et al 2001, Thibaudin et al 2004. In general, these studies are notable for the fact that most have examined a relatively limited number of patients (often less than 100) and that most report a positive association of a particular SNP with disease onset or course, usually at the 0.05 significance level.…”

Section: Discussionmentioning

confidence: 99%

PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy

Bicanski

Wenderdel²,

Mertens³

et al. 2007

View full text Add to dashboard Cite

Background: Few genetic factors have been identified that determine susceptibility to and progression of IgA-nephropathy (IgAN). Given that IgAN is usually characterized by mesangioproliferative glomerulonephritis and that PDGF-B is of central pathophysiological relevance in this process, we analyzed four single-nucleotide polymorphisms (SNPs) of the PDGF-B gene to evaluate a possible association of these SNPs with disease onset and progression, histological grading and responses to ACE inhibitor (ACEi) therapy. Methods: The total study population consisted of 195 IgAN patients (127 from southern Italy and 68 from northern Germany) and 200 healthy controls (100 from each region). All four SNPs were in Hardy-Weinberg equilibrium and genotype distributions did not differ between patients and controls in either region. Results: SNP distribution in Italian patients reaching endstage renal disease (n = 45) also was not significantly different from patients maintaining a serum creatinine below 1.2 mg/dl (n = 60) during 5.6 ± 5.5 years of follow-up. Furthermore, we failed to detect significant effects of any SNP on the slope of 1/serum creatinine, proteinuria level or the antiproteinuric response to ACEi. Additionally, particular PDGF-B genotypes did not correlate with histological grading using the Lee classification. Conclusion: We conclude that none of the four PDGF-B SNPs is related to the onset of IgAN in two different populations and that none of them has a major influence on the course of IgAN.

show abstract

Advances in Genetics of Immunoglobulin A Nephropathy

Zhang

Magistroni

Gharavi

2016

Pathogenesis and Treatment in IgA Nephropathy

View full text Add to dashboard Cite

Influence of β<sub>3</sub> Integrin Gene Leu<sup>33</sup>/Pro<sup>33</sup> Polymorphism on Primary Glomerulonephritis

Cited by 3 publications

References 30 publications

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis

Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis

PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy

Advances in Genetics of Immunoglobulin A Nephropathy

Contact Info

Product

Resources

About